Open AccessPost‐COVID‐19 co‐morbidity of emerged Lophomonas infection and invasive pulmonary aspergillosis: First case report
Author(s) -
Sharifpour Ali,
Zakariaei Zakaria,
Fakhar Mahdi,
Banimostafavi Elham Sadat,
Nakhaei Maryam,
Soleymani Mostafa
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4822
Subject(s) - medicine , covid-19 , pulmonary aspergillosis , aspergillosis , pulmonary infection , intensive care medicine , immunology , pathology , infectious disease (medical specialty) , disease , outbreak
Due to long corticosteroid therapy in patients with COVID‐19, in case of cough, dyspnea, and weight loss, emerging pulmonary aspergillosis and lophomoniasis should be ruled out.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom